Sign-up for Kamada Announces Positive Interim Results from Phase I/II Clinical Study of its Human Alpha-1 Antitrypsin to Treat Graft-versus-Host Disease Presented at the American Society of Hematology Annual Meeting investment picks
Sign-up for OncoMed to Present New and Emerging Data From Demcizumab (anti-DLL4, OMP-21M18) and Tarextumab (anti-Notch2/3, OMP-59R5) Clinical Studies at the European Society for Medical Oncology 2014 Congress investment picks
AVEO Oncology (NASDAQ:AVEO) today announced poster presentations for two
Phase 2 clinical studies of tivozanib, one in metastatic colorectal
cancer (mCRC) and one in renal cell carcinoma (RCC), at the 2014
Congress of the European Society for Medical Oncology (ESMO), taking
place September 25–30 in Madrid, Spain.
MIAMI , October 9, 2014 /PRNewswire/ -- Technology Applications International Corporation (OTCBB: NUUU) (the "Company" or "NUUU") announced today that they a concluded a clinical study to test the efficacy of their products at Essex Testing Clinic in Verona, NJ .
Sign-up for NUUU Announces the Results of a Clinical Study that Tested the Efficacy of its Wholly Owned Subsidiary's Rejuvel Line of Anti-Aging Products that use NASA* Patented Technology investment picks
Merck (NYSE:MRK), known as MSD outside the United States and Canada,
today announced that new data from clinical studies of the company’s
investigational, oral, once-daily, fixed-dose combination chronic
hepatitis C treatment grazoprevir/elbasvir (MK-5172/MK-8742) are
scheduled to be presented at the 65 th American Association
for the Study of Liver Diseases (AASLD) Annual Meeting, also known as
The Liver Meeting ® .
Sign-up for Merck to Present New Data from Clinical Studies Evaluating Investigational Hepatitis C Treatment Grazoprevir/Elbasvir (MK-5172/MK-8742) at the 65th American Association for the Study of Liver Diseases Annual Meeting investment picks
Sarepta Therapeutics, Inc. (NASDAQ: SRPT), a developer of innovative
RNA-based therapeutics, today announced the publication of results from
two single ascending-dose studies that demonstrated no clinical or
toxicologic safety concerns with the company’s drug candidates for the
treatment of Ebola and Marburg virus, respectively.
Orthofix International N.V., (NASDAQ:OFIX), today announced the
Company’s first large-scale clinical study to evaluate the use of pulsed
electromagnetic fields (PEMF) technology to see if the therapy can
improve osteogenesis (bone growth) in Type II odontoid fractures.
Results of two clinical studies of the LuViva® Advanced Cervical Scan
showed the versatility of the technology in its ability to screen the
general population for cervical cancer and to eliminate unnecessary
testing for women who are screened by other methods.
Pharmaceuticals, Inc. (NASDAQ: IRWD) announced today that dosing has
begun in a Phase IIa clinical study evaluating whether its
investigational guanylate cyclase-C (GC-C) agonist, IW-9179, can provide
symptomatic relief to patients with diabetic gastroparesis.
Ipsen (Euronext: IPN; ADR: IPSEY) today announced positive results from
the phase III study of triptorelin pamoate 11.25 mg (Decapeptyl ®
3 months) administered subcutaneously in patients with locally advanced
or metastatic prostate cancer at the European Association of Urology
(EAU) 14 th Central European Meeting in Cracow, Poland (10-12
The primary objective of the study was to assess the efficacy and safety
profile of the sustained-release triptorelin pamoate 11.25 mg (Decapeptyl ®
3 months) formulation when administered by the subcutaneous route in men
with locally advanced or metastatic prostate cancer.
Independent. Insightful. Trusted. Morningstar provides stock market analysis; equity, mutual fund, and ETF research, ratings, and picks; portfolio tools; and option, hedge fund, IRA, 401k, and 529 plan research. Our reliable data and analysis can help both experienced enthusiasts and newcomers.